ClinicalTrials.gg
RecruitingNCT06696170Updated May 5, 2026

CellFX® Nanosecond Pulsed Field Ablation (PFA) 360 Catheter Ablation System for Treatment of Atrial Fibrillation

An interventional study of CellFX nano-pFA 360 Endocardial Ablation Catheter System in Atrial Fibrillation Paroxysmal, Cardiac Ablation and Cardiac Arrhythmia, sponsored by Pulse Biosciences, Inc.. Recruiting at 3 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Pulse Biosciences, Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Registered 3 months after the study started (first participant enrolled Jul 2024, registered Nov 2024).
  • Started Jul 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 205 studies in Atrial Fibrillation with a site in Belgium — 34 open to participants now, 52 under way, 1 of them phase 3. Atrial Fibrillation · Belgium.

Planned enrollment
142nd of 160
60 · median 296
Started
2024
with 10 others
No phase
102 of 205
22 open now
Primary completion
2026-06
later than 10 of 51 live
Registered
181st of 205
by date

Among the 205 studies in Atrial Fibrillation with a site in Belgium, this one is the 142nd largest by planned enrollment of the 160 interventional ones that give a count, is one of 11 that started in 2024, is one of 102 with no phase, reaches primary completion later than 10 of the 51 other live ones, and was the 181st registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

34 of the 205 studies in Atrial Fibrillation with a site in Belgium are open now. Recruiting first, the newest first:

28 more — sign in →

All 34 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 205 studies in Atrial Fibrillation with a site in Belgium, or all of them as a file.
02

Study summary

The objective of this study is to demonstrate initial safety and effectiveness of the CellFX nano-second Pulsed Field Ablation (nsPFA or nano-PFA) 360 Catheter Endocardial Ablation System in treating subjects with atrial fibrillation.

Read the detailed description

This study is a prospective, non-randomized, open labelled, single-arm first-in-human (FIH) feasibility study to evaluate the initial clinical safety and device performance of the nano-PFA 360 Catheter Endocardial Ablation System for the treatment of atrial fibrillation. Enrolled subjects will be followed for up to 12 months post-nano PFA 360 Catheter Ablation. All subjects will undergo an electroanatomical mapping procedure post-ablation to evaluate immediate pulmonary vein isolation (PVI) and at 3 months post-index procedure to assess electrical isolation of the pulmonary veins.

03

Conditions studied

  • Atrial Fibrillation Paroxysmal
  • Cardiac Ablation
  • Cardiac Arrhythmia

Keywords

  • nsPFA
  • CellFX
  • Pulsed Field Ablation
  • nano-PFA
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must be ≥ 18 and ≤ 75 years of age on the day of enrollment
  • Subject is willing and capable of providing to undergo study procedures and participate in all examinations and follow-up visits and tests associated with this clinical study
  • Subjects with PAF who have had at least one AF episode documented within one (1) year prior to enrollment. Documentation may include , transtelephonic monitor (TTM), Holter monitor (HM), or telemetry strip
  • Subjects who have failed at least one antiarrhythmic drug (AAD; class I or III, or AV nodal blocking agents such as beta blockers and calcium channel blockers) as shown by recurrent symptomatic AF, or intolerance to the AAD or AV nodal blocking agents
  • Antero-posterior left atrial diameter ≤ 5.5 cm as documented by transthoracic echocardiography (TTE) or computed tomography (CT) within 3 months prior to the procedure
  • ≥ 40% as documented by TTE within 12 months prior to the procedure
  • Received a standard cardiac work up and is an appropriate candidate for an procedure as determined by the study investigators

Exclusion criteria

Exclusion Criteria:

  • Subject has an implantable electronic medical device. (i.e., pacemaker, ICD or CRT) or left atrial appendage device
  • Subject has a prosthetic heart valve
  • AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause
  • AF episodes lasting > 7 days
  • Previous ablation for AF
  • Subjects on amiodarone at any time during the past 3 months prior to enrollment
  • Prior history of pericarditis or pericarditis within 3 months based on the TTE examination
  • Prior history of rheumatic fever
  • Prior history of medical procedure involving instrumentation of the left atrium (previous ablation, atrial septal defect (ASD) closure, left atrial appendage occlusion)
  • History of severe chronic gastrointestinal problems involving the esophagus, stomach and/or untreated acid reflux
  • History of abnormal bleeding and/or clotting disorder
  • to anticoagulation (i.e., Heparin, Dabigatran, Apixaban, Vitamin K Antagonists such as Warfarin)
  • Active or history of treated cancer within 24 months of enrollment
  • infection or sepsis on the day of index procedure with either fever, leukocytosis or requiring intravenous antibiotics
  • History of stroke or within prior 6 months, or any prior intracranial hemorrhage or permanent neurological deficit
  • (NYHA) class IIIb or IV congestive heart failure and/or any heart failure hospitalization within 3 months prior to enrollment
  • > 35 kg/m2
  • Estimate (eGFR) \< 60 mL/min/1.73 m2 or has ever received hemodialysis
  • History of untreated and serious hypotension, bradycardia or chronotropic incompetence
  • Any of the following within 3 months of enrollment:

    1. Major surgery except for the index procedure
    2. Myocardial infarction
    3. Unstable angina
    4. Percutaneous coronary intervention
    5. Sudden cardiac death event
    6. Left atrial thrombus that has not resolved as shown by TEE or CT
  • Solid organ or hematologic transplant, or currently being evaluated for an organ transplant
  • History of pulmonary hypertension with pulmonary systolic artery pressure >50 mm Hg, severe or restrictive lung disease
  • Subjects with any other significant uncontrolled or unstable medical condition (such as uncontrolled brady-arrhythmias, ventricular arrhythmias, hyperthyroidism or significant coagulation disorder)
  • less than one year
  • Clinically significant psychological condition that in the physician's opinion would prohibit the subject's ability to meet the protocol requirements.
  • Females of who are nursing, pregnant, or planning to become pregnant during the study period
  • Other criteria, which the Investigator determines would make the patient unsuitable to participate (e.g. uncontrolled drug and/or alcohol addiction, congenital disease, fragility)
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    CellFX nano-PFA Treatment Arm

    CellFX nano-PFA 360 Endocardial Ablation Catheter System

    Device: CellFX nano-pFA 360 Endocardial Ablation Catheter System

Interventions

  • DeviceCellFX nano-pFA 360 Endocardial Ablation Catheter System

    The CellFX nano-PFA 360 Endocardial Ablation Catheter System includes the nano-pFA 360 Endocardial Ablation Catheter, CellFX Console, switcher box/adapter, and sensing cable. The System is a proprietary endocardial catheter system designed for use in cardiac electrophysiology procedures for the treatment of arrhythmias, including atrial fibrillation. The nano-PFA 360 Catheter ablates cardiac tissue using nonthermal nano-second pulses of electrical energy. Nanosecond Pulsed Field Ablation (nsPFA or nano-PFA) is a cell-specific, nonthermal ablation technology that delivers nanosecond-duration pulses of high-amplitude electrical energy to tissue via bipolar electrodes. The pulses disrupt the ability of the cell and internal organelles to maintain cellular homeostasis by creating nanopores in lipid membranes, ultimately leading to regulated cell death (RCD).

06

What researchers measure

Primary outcomes

  1. Rate of primary safety major adverse events (MAEs)

    The primary safety endpoint includes major adverse events (MAEs) specifically related to the device or ablation procedure for the following * Asymptomatic Cerebral Embolism * Arterioesophageal Fistula * Bleeding Requiring Transfusion * Cardiac Perforation/Tamponade * Death * Esophageal Injury Resulting in Perforation * Myocardial Infarction * Pericarditis Requiring Intervention or Hospitalization * Phrenic Nerve Injury/Diaphragmatic Paralysis * Pulmonary Edema/Respiratory Insufficiency * Pulmonary Vein Stenosis (≥70% diameter reduction) * Stroke or Transient Ischemic Attack * Vagal Nerve Injury Resulting in Esophageal Dysmotility or Gastroparesis * Vascular Access Complication Requiring Intervention

    Time frame: Within 30 days post-ablation procedure

  2. Proportion of participants achieving acute procedural success.

    Acute procedural success is achieving entrance block of the pulmonary veins

    Time frame: Immediately post-ablation procedure

Secondary outcomes

  1. Proportion of participants reporting one or more significant adverse events (SAEs)

    Safety related to the reporting one or more SAEs for each follow-up interval as described. * Atrio-esophageal fistula (up to 3-month visit) * Pulmonary Vein (PV) stenosis (up to 3-month visit) * Subjects presenting with Primary SAEs up to the 12-month post- procedure follow-up * Subjects presenting with any AEs or SAEs up to the 12-month post- procedure follow-up

    Time frame: Within 12 months post-ablation procedure

  2. Proportion of participants achieving long-term technical success

    Long-term technical success is defined as electrical isolation of the pulmonary veins (PVI) assessed during an electroanatomical mapping procedure.

    Time frame: Within 3 months post-ablation procedure

  3. Proportion of participants achieving treatment success

    Treatment success is defined by freedom from the following failures: 1. Recurrence of atrial fibrillation, atrial flutter, atrial tachycardia (AF/AFL/AT) as evidenced by episodes ≥ 30 secs on transtelephonic monitoring (TTM), Holter monitoring, or continuously 12-lead electrocardiogram (ECG) 2. Cardioversion for atrial fibrillation (AF) /atrial flutter (AFL) / atrial tachycardia (AT) 3. Repeat ablation failure 4. Antiarrhythmic Drugs (AADs) failure 5. Surgical treatment for AF/AFL/AT after the index procedure

    Time frame: Within 12 months post-ablation procedure

07

Study locations

2 of 3 sites recruiting
  • Hartcentrum Hasselt Research Center /Jessa Hospital
    Hasselt, Belgium
    Active, not recruiting

    Not enrolling at this site.

  • Na Homolce Hospital
    Prague, Czechia
    Recruiting
    • Štěpán Královec · Contact
    • Prof. Petr Neuzil, MD, PhD · Principal investigator
  • Policlinico Tor Vergata Hospital
    Roma, Italy
    Recruiting
    • Giuseppe Stifano, MD, PhD · Contact
    • Prof. Andrea Natale, MD · Principal investigator
08

References and documents

Publications

  • Reddy VY, Petru J, Vijgen J, Turagam M, Koruth JS, Funasako M, Hala P, Koopman P, Skoda J, Stifano G, La Fazia MV, Kenigsberg D, Natale A, Neuzil P. High-Voltage Nanosecond Pulse Field Ablation Using a Compliant Circular Catheter to Treat Atrial Fibrillation: Lesion Durability and One-Year Outcomes. JACC Clin Electrophysiol. 2026 Apr 25:S2405-500X(26)00367-1. doi: 10.1016/j.jacep.2026.04.012. Online ahead of print. PubMed 42175980 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jun 2026, 23 months after the start.

Of 255 industry-sponsored interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's planned 23 months is close to that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2024
First posted
Nov 20, 2024
StartActual
Jul 25, 2024
Primary completionEst.
Jun 25, 2026
CompletionEst.
Jul 25, 2026
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06696170
Lead sponsor
Pulse Biosciences, Inc.
Responsible party
Sponsor
First posted
Nov 20, 2024
Start date
Jul 25, 2024
Primary completion
Jun 25, 2026 (estimated)
Completion
Jul 25, 2026 (estimated)
Last update
May 5, 2026

Study contacts

William A. Knape
Contact
bknape@pulsebiosciences.com
510-906-4649
Aleksandra Kurek
Contact
aleksandra.kurek@pulsebiosciences.com
+44 745 6655949
Rich A. Nuccitelli, PhD
study director · Pulse Biosciences, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion